Business
Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day
Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will
About this update from Dexcom, Inc.
[{"type":"text","content":"\nWill Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date\n\n\nReconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap\n\n\nInitiatives Follow Constructive Engagement with Elliott Management\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth.\n\n\n“We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms,” said Jake Leach, Dexcom’s president and CEO. “Today’s announcement of enhancements to our Board structure aligns closely to our vision for uncompromising quality and customer experience, as well as updates we’ve made to our organizational structure to support the execution of our long-term plan.”\n\n\nDexcom and Elliott Investment Management L.P. (together with its affiliates, “Elliott”) have agreed to collaborate to identify two new independent members to join the Board of Directors. To this end, Dexcom has initiated a search focusing on leaders with MedTech leadership or lean operations experience. These directors, alongside the existing Board members, will provide additional oversight and support to management as the company embraces its significant long-term opportunity and global customer growth ambitions. With these appointments, the Board will have appointed six new independent directors since the beginning of 2023.\n\n\n“Our Board is always focused on continual refreshment that adds the skills and experience that will take our company to the next level,” said Mark Foletta, Lead Independent Director. “We are excited to announce this plan to further bolster our Board’s composition.”\n\n\nIn addition, the company announced the existing Technology Committee on the Board will become the Operations and Innovation Committee. The renamed committee will expand its mandate to enhance the Board’s focus on the company’s crucial scaling efforts, including operations and quality, in addition to its technical roadmap.\n\n\n“We are one of Dexcom’s largest investors because of our conviction...